Interestingly, there is very limited reports of efficacy of recombinant IL-1Ra or IL-1β inhibitors in animal models (except for IL1RN deficiency model), which are both approved biologics in SJIA. The gene discussed is IL1RN; the disease is hyperinsulinemic hypoglycemia, familial, 4.